Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin.

Erbitux (cetuximab) - Eli Lilly

xevinapant (Debio 1143) - EMD Serono

cisplatin - Generic mfg.

http://www.ncbi.nlm.nih.gov/pubmed/41903611

A Larnaudie; C Hugo; F Rolland; J Bourhis; P Boisselier; X S Sun; Y Pointreau; Y Tao

Mar 29, 2026